These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9721789)

  • 21. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of factor V Leiden carriage on maternal and fetal health.
    Bloomenthal D; von Dadelszen P; Liston R; Magee L; Tsang P
    CMAJ; 2002 Jul; 167(1):48-54. PubMed ID: 12137081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
    Rodeghiero F; Tosetto A
    Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
    Weitz IC; Israel VK; Liebman HA
    Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
    Yan SB; Nelson DR
    Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
    Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
    Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in activated protein C resistance during normal pregnancy.
    Walker MC; Garner PR; Keely EJ; Rock GA; Reis MD
    Am J Obstet Gynecol; 1997 Jul; 177(1):162-9. PubMed ID: 9240601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
    Mandel H; Brenner B; Berant M; Rosenberg N; Lanir N; Jakobs C; Fowler B; Seligsohn U
    N Engl J Med; 1996 Mar; 334(12):763-8. PubMed ID: 8592550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preeclampsia is associated with a reduced response to activated protein C.
    Lindoff C; Ingemarsson I; Martinsson G; Segelmark M; Thysell H; Astedt B
    Am J Obstet Gynecol; 1997 Feb; 176(2):457-60. PubMed ID: 9065198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
    Kraus M; Zander N; Fickenscher K
    Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
    Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
    Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel factor V mutation causes a normal activated protein C ratio despite the presence of a heterozygous F5 R506Q (factor V Leiden) mutation.
    Prüller F; Raggam RB; Mangge H; Truschnig-Wilders M; Matzhold EM; Weiss EC; Hasiba B; Summers KL; Renner W; Siegert G; Kostka H
    Br J Haematol; 2013 Nov; 163(3):414-7. PubMed ID: 23957718
    [No Abstract]   [Full Text] [Related]  

  • 36. Third trimester nonrecurrent fetal loss is associated with factor V Leiden and prothrombin gene mutations.
    Karateke A; Haliloglu B; Gurbuz A
    J Matern Fetal Neonatal Med; 2005 Nov; 18(5):299-304. PubMed ID: 16390788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
    Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC
    Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated-protein-C resistance in cancer patients.
    Green D; Maliekel K; Sushko E; Akhtar R; Soff GA
    Haemostasis; 1997; 27(3):112-8. PubMed ID: 9306127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
    El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
    Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
    Vandenbroucke JP; Koster T; Briët E; Reitsma PH; Bertina RM; Rosendaal FR
    Lancet; 1994 Nov; 344(8935):1453-7. PubMed ID: 7968118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.